I. Lauer
Research Subjects
Research Interests
I. Lauer has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
H Kosmehl
2 shared publications- Peter Sieg
Department of Maxillofacial Surgery, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538 Luebeck, Germany
2 shared publications - Angela Berndt
Institute of Pathology, Friedrich Schiller University, Jena, Germany
1 shared publication B. Melier
From the Department of Radiotherapy and Nuclear Medicine. Medical University of Lübeck. Germany
1 shared publicationE. Richter
From the Department of Radiotherapy and Nuclear Medicine. Medical University of Lübeck. Germany
1 shared publication- Gerd Geerling
Department of Ophthalmology, University of Lübeck, Lübeck, Germany
1 shared publication
Latest Publications
- 3 November 2004
- Vol. 24, 2841-6
Re-distribution of tenascin-C in the parotid acinar cells. An early marker of radiation-induced damage of salivary glands?
In order to investigate the early changes in the expression of tenascin-C, following irradiation and the associated functional impairment of salivary glands. Fifteen rabbits were used for the study. Five provided control parotid gland tissue and a further 10 rabbits were scintigraphically examined prior to and 24 h after 15/30 Gy. Glands were studied histologically using HE-staining and tenascin-C antibodies. Reduction in the salivary ejection fraction (SEF) was observed in all irradiated glands. Simultaneously, a marked re-distribution of tenascin-C expression was noticed. Reactivity detected in the intercalated, secretory ducts and perineurinal regions prior to radiation was noticed intracellularly after 24 h. Furthermore, nerves showed tenascin-C expression in the Schwann cells, but no longer perineurinally. Myofibroblasts were also observed in the stroma. This study proves the ability to predict functional disorders of salivary function as early as 24 h after radiation and provides evidence of the participation of tenascin-C in the pathological process of radiation-induced damage in salivary glands.
- 3 November 2004
- Vol. 24, 2841-6
Re-distribution of tenascin-C in the parotid acinar cells. An early marker of radiation-induced damage of salivary glands?
In order to investigate the early changes in the expression of tenascin-C, following irradiation and the associated functional impairment of salivary glands. Fifteen rabbits were used for the study. Five provided control parotid gland tissue and a further 10 rabbits were scintigraphically examined prior to and 24 h after 15/30 Gy. Glands were studied histologically using HE-staining and tenascin-C antibodies. Reduction in the salivary ejection fraction (SEF) was observed in all irradiated glands. Simultaneously, a marked re-distribution of tenascin-C expression was noticed. Reactivity detected in the intercalated, secretory ducts and perineurinal regions prior to radiation was noticed intracellularly after 24 h. Furthermore, nerves showed tenascin-C expression in the Schwann cells, but no longer perineurinally. Myofibroblasts were also observed in the stroma. This study proves the ability to predict functional disorders of salivary function as early as 24 h after radiation and provides evidence of the participation of tenascin-C in the pathological process of radiation-induced damage in salivary glands.
- 1 September 2000
- Vol. 106 (3) , 554
Microvascular submandibular gland transfer for severe cases of keratoconjunctivitis sicca.
Free submandibular salivary gland transfer was investigated as a surgical method for the treatment of severe keratoconjunctivitis sicca. In an animal model, we examined the tolerance of warm ischemia of the submandibular gland. After temporary interruption of the blood supply (1 to 6 hours), the morphologic changes in the submandibular gland were analyzed histologically and immunohistochemically in 41 rabbits. From 1.5 hours ischemia onward, an increasing structural damage of the parenchyma with emphasis on the secretory cells was seen. Six hours of ischemia caused total necrosis of the salivary gland. Our clinical experience includes 24 highly selected patients suffering from keratoconjunctivitis sicca, in whom we transferred 31 autologous submandibular glands to the temple for permanent autologous tear substitution within the past 4 years. The glands were implanted into a pocket prepared in the temporalis muscle, and the nourishing vessels were anastomosed to the superficial temporal artery and vein. The submandibular duct was implanted into the upper lateral conjunctival fornix. The transferred glands were left denervated. In addition to the clinical examination, scintigraphy with Tc 99m pertechnetate was used to document the graft's viability after the transfer. Viable incorporation with longstanding secretory function occurred in 26 of the 30 transplanted denervated salivary glands. The resulting lubrication of the treated eyes was irregular for up to 3 months in almost even case. One year after surgery, all patients with a viable transplant developed at least occasional epiphora, which was surgically managed by reducing the size of the graft in 10 patients. No severe side effects were seen in this series. The ophthalmologic evaluation of the method included the assessment of dry eye symptoms and of the volume and quality of ocular lubrication (Schirmer test, fluorescein break-up time), the pathology of the ocular surface (rose bengal staining), and the need for pharmaceutical tear substitutes. One year after surgery, 18 of 27 cases assessed were judged as significantly improved by these tests.
- 1 September 2000
- Vol. 106 (3) , 554
Microvascular submandibular gland transfer for severe cases of keratoconjunctivitis sicca.
Free submandibular salivary gland transfer was investigated as a surgical method for the treatment of severe keratoconjunctivitis sicca. In an animal model, we examined the tolerance of warm ischemia of the submandibular gland. After temporary interruption of the blood supply (1 to 6 hours), the morphologic changes in the submandibular gland were analyzed histologically and immunohistochemically in 41 rabbits. From 1.5 hours ischemia onward, an increasing structural damage of the parenchyma with emphasis on the secretory cells was seen. Six hours of ischemia caused total necrosis of the salivary gland. Our clinical experience includes 24 highly selected patients suffering from keratoconjunctivitis sicca, in whom we transferred 31 autologous submandibular glands to the temple for permanent autologous tear substitution within the past 4 years. The glands were implanted into a pocket prepared in the temporalis muscle, and the nourishing vessels were anastomosed to the superficial temporal artery and vein. The submandibular duct was implanted into the upper lateral conjunctival fornix. The transferred glands were left denervated. In addition to the clinical examination, scintigraphy with Tc 99m pertechnetate was used to document the graft's viability after the transfer. Viable incorporation with longstanding secretory function occurred in 26 of the 30 transplanted denervated salivary glands. The resulting lubrication of the treated eyes was irregular for up to 3 months in almost even case. One year after surgery, all patients with a viable transplant developed at least occasional epiphora, which was surgically managed by reducing the size of the graft in 10 patients. No severe side effects were seen in this series. The ophthalmologic evaluation of the method included the assessment of dry eye symptoms and of the volume and quality of ocular lubrication (Schirmer test, fluorescein break-up time), the pathology of the ocular surface (rose bengal staining), and the need for pharmaceutical tear substitutes. One year after surgery, 18 of 27 cases assessed were judged as significantly improved by these tests.
- 1 January 1998
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 37 (03) , 107-112
Influence of Radioiodine Therapy on Urinary Iodine Excretion
Aim: In 214 patients with benign thyroid diseases the time-course of urinary iodine excretion (UIE) was investigated in order to identify changes after radioiodine therapy (RITh). Method: UIE was measured photometrically (cerium-arsenite method) and related to urinary creatinine on the first and last day of the radioiodine test and then three days, seven days, four weeks, and six months after 1311 administration. Results: As compared with the level found immediately before radioiodine therapy, median UIE had almost doubled four weeks after therapy and was still significantly elevated six months after therapy. This increase correlated significantly with the target volume as measured by scintigraphy and sonography. Conclusions: The persistent elevation of UIE for months after RITh is a measure of treatment-induced damage to thyrocytes. Therefore, in view of the unfavourable kinetics of iodine that follow it, RITh should if possible be given via a single-dose regime. Ziel: Bei 214 Patienten mit benignen Schilddrüsenerkrankungen wurde der Verlauf der Uriniodausscheidung (UIA) nach Radioiodtherapie untersucht, um posttherapeutische Änderungen der lodausscheidung nachzuweisen. Methode: Die UIA wurde am ersten und letzten Tag des Radioiodtestes sowie drei und sieben Tage, vier Wochen und sechs Monate nach 1311-Applikation photometrisch (Cer-Arsenit-Methode) bestimmt und auf den Kreatiningehalt bezogen. Ergebnisse: Die Uriniodausscheidung stieg nach der Radioiodtherapie signifikant an. Vier Wochen nach Therapie wurden im Median fast doppelt so hohe Werte der UIA gefunden wie unmittelbar davor. Auch sechs Monate nach Therapie war die Uriniodausscheidung noch signifikant erhöht. Diese Zunahme war signifikant mit dem szinti- und sonographisch bestimmten Zielvolumen verknüpft. Schlußfolgerungen: Die noch über Monate erhöhte Uriniodauscheidung nach Radioiodtherapie ist ein Maß für die therapiebedingte Schädigung der Thyreozyten. Daher müssen Radioiod- therapien auch wegen der posttherapeutisch ungünstigen lodkinetik möglichst einzeitig durchgeführt werden.
- 1 January 1998
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 37 (03) , 107-112
Influence of Radioiodine Therapy on Urinary Iodine Excretion
Aim: In 214 patients with benign thyroid diseases the time-course of urinary iodine excretion (UIE) was investigated in order to identify changes after radioiodine therapy (RITh). Method: UIE was measured photometrically (cerium-arsenite method) and related to urinary creatinine on the first and last day of the radioiodine test and then three days, seven days, four weeks, and six months after 1311 administration. Results: As compared with the level found immediately before radioiodine therapy, median UIE had almost doubled four weeks after therapy and was still significantly elevated six months after therapy. This increase correlated significantly with the target volume as measured by scintigraphy and sonography. Conclusions: The persistent elevation of UIE for months after RITh is a measure of treatment-induced damage to thyrocytes. Therefore, in view of the unfavourable kinetics of iodine that follow it, RITh should if possible be given via a single-dose regime. Ziel: Bei 214 Patienten mit benignen Schilddrüsenerkrankungen wurde der Verlauf der Uriniodausscheidung (UIA) nach Radioiodtherapie untersucht, um posttherapeutische Änderungen der lodausscheidung nachzuweisen. Methode: Die UIA wurde am ersten und letzten Tag des Radioiodtestes sowie drei und sieben Tage, vier Wochen und sechs Monate nach 1311-Applikation photometrisch (Cer-Arsenit-Methode) bestimmt und auf den Kreatiningehalt bezogen. Ergebnisse: Die Uriniodausscheidung stieg nach der Radioiodtherapie signifikant an. Vier Wochen nach Therapie wurden im Median fast doppelt so hohe Werte der UIA gefunden wie unmittelbar davor. Auch sechs Monate nach Therapie war die Uriniodausscheidung noch signifikant erhöht. Diese Zunahme war signifikant mit dem szinti- und sonographisch bestimmten Zielvolumen verknüpft. Schlußfolgerungen: Die noch über Monate erhöhte Uriniodauscheidung nach Radioiodtherapie ist ein Maß für die therapiebedingte Schädigung der Thyreozyten. Daher müssen Radioiod- therapien auch wegen der posttherapeutisch ungünstigen lodkinetik möglichst einzeitig durchgeführt werden.